Abstract: The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an anti-phospholipase A2 receptor (PLA2R) autoantibody-based B cell receptor, polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant T cells comprising the CAAR. The invention also includes methods of making a genetically modified cell, e.g., a genetically modified T cell, expressing a PLA2R-CAAR wherein the expressed CAAR comprises a PLA2R extracellular domain.

Abstract: The disclosure provides improved X-bars and end frames that can prevent or at least reduce sagging in conveyors, such as flexible conveyors. The improved X-bars and end frames are referred to as riveted X-bars and leg plates, respectively. An expandable conveyor system, an expandable conveyor segment, and a riveted assembly are disclosed. Expandable conveyor segments can be coupled together via a riveted assembly to form an expandable conveyor system. In one example, the riveted assembly includes; (1) a leg plate and (2) two riveted x-bars connected to the leg plate via at least one slot insert.

Abstract: The disclosure provides an automated process, apparatus and system for decanting containers wherein the form of the container is altered during the decanting process. The decanting includes altering the form of the containers for the separation or removal of the product from the containers. The altering can include a pushing motion, a pulling motion, or both on one or more sides of the containers. In one example, a method of automatically decanting products from containers includes: (1) opening a portion of a container, (2) lifting and rotating the container using a robotic depositing device, and (3) separating product from the container after the lifting and rotating by altering a form of the container using the robotic depositing device.

Abstract: A reinforced thermoplastic pipe (RTP), RTP body, and a method of providing RTP body are disclosed. The method of providing RTP body for storage and/or transportation of a fluid, comprises providing a first pipe body layer; providing a further pipe body layer coaxial with the first pipe body layer; providing a plurality of helically wound wire elements disposed between the first pipe body layer and the further pipe body layer; heating surrounding precursor thermoplastic material via Joule heating of the wire elements thereby providing viscous state thermoplastic polymer at least one of a first interface location between the first pipe body layer and the further pipe body layer; and subsequently cooling the viscous state thermoplastic polymer for joint consolidation thereby consolidating RTP body over at least a portion of a whole length of the RTP body.

Abstract: The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an anti-phospholipase A2 receptor (PLA2R) autoantibody-based B cell receptor, polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant T cells comprising the CAAR. The invention also includes methods of making a genetically modified cell, e.g., a genetically modified T cell, expressing a PLA2R-CAAR wherein the expressed CAAR comprises a PLA2R extracellular domain.

Abstract: The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an anti-phospholipase A2 receptor (PLA2R) autoantibody-based B cell receptor, polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant T cells comprising the CAAR. The invention also includes methods of making a genetically modified cell, e.g., a genetically modified T cell, expressing a PLA2R-CAAR wherein the expressed CAAR comprises a PLA2R extracellular domain.

Abstract: The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an anti-phospholipase A2 receptor (PLA2R) autoantibody-based B cell receptor, polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant T cells comprising the CAAR. The invention also includes methods of making a genetically modified cell, e.g., a genetically modified T cell, expressing a PLA2R-CAAR wherein the expressed CAAR comprises a PLA2R extracellular domain.